Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 3/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | GLI1 | P08151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8795414 | 0.90 | LMNA (0.44) | LMNAKMT2AGRM1MAPTALDH1A1 | |
| SCHEMBL2551174 | 0.88 | EPHX1 (0.35) | LMNAEPHX1KMT2AGRM1MAPT | |
| SCHEMBL3764733 | 0.85 | MEN1 (0.37) | LMNAKMT2AMEN1CYP1A2CYP2D6 | |
| SCHEMBL3774101 | 0.85 | MEN1 (0.37) | LMNAKMT2AMEN1CYP1A2CYP2D6 | |
| SCHEMBL6078824 | 0.85 | MEN1 (0.37) | LMNAKMT2AMEN1CYP1A2CYP2D6 | |
| SCHEMBL24516573 | 0.85 | MEN1 (0.37) | LMNAKMT2AMEN1CYP1A2CYP2D6 | |
| SCHEMBL6078829 | 0.85 | MEN1 (0.37) | LMNAKMT2AMEN1CYP1A2CYP2D6 | |
| SCHEMBL8795610 | 0.84 | MEN1 (0.47) | KMT2AMAPTALDH1A1MEN1CYP1A2 | |
| SCHEMBL2971171 | 0.83 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL3985977 | 0.83 | EPHX1 (0.30) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426770-B2 | Process for the preparation of Lurasidone hydrochloride | Jubilant Generics Limited (IN) | 2019-10-01 | — | — | US | claimed |
| US-20170246165-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | Jubilant Generics Limited (IN) | 2017-08-31 | — | — | US | claimed |
| CN-110183639-B | Preparation method and application of catalyst for polyester synthesis | 华东理工大学 | 2022-10-11 | — | — | CN | disclosed |
| US-10426770-B2 | Process for the preparation of Lurasidone hydrochloride | Jubilant Generics Limited (IN) | 2019-10-01 | — | — | US | disclosed |
| CN-110183639-A | A kind of preparation method and applications of the catalyst for polyester synthesis | 华东理工大学 | 2019-08-30 | — | — | CN | disclosed |
| EP-3436449-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-9975902-B2 | Compounds for the inhibition of cyclophilins and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| WO-2017173052-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283427-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20170246165-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | Jubilant Generics Limited (IN) | 2017-08-31 | — | — | US | disclosed |
| EP-3207041-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) (IN) | 2017-08-23 | — | — | EP | disclosed |
| US-4948799-A | ANTIPSYCHOTIC DRUGS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-08-14 | — | — | US | disclosed |
| US-4843078-A | ANXIOLYTIC AGENTS | SUMITONO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0314098-A2 | Imide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| US-4812461-A | Imide derivatives and their use in the treatment psychosis | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-03-14 | — | — | US | disclosed |
| US-4745117-A | NEUROLEPTIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-05-17 | — | — | US | disclosed |
| EP-0261688-A1 | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-03-30 | — | — | EP | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
| EP-0196096-A2 | Imide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-10-01 | — | — | EP | disclosed |
| EP-0082402-A2 | Succinimide derivates and process for preparation thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246165-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE | FFAR3, FAR1, PRLHR | LMNA 3360/4885EPHX1 2165/4885KMT2A 3427/4885 |
| US-20170283427-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | PPIG, PPIH, FKBP2 | LMNA 3360/4885EPHX1 412/4885KMT2A 4781/4885 |
| US-10426770-B2 | Process for the preparation of Lurasidone hydrochloride | FFAR3, REN, LSS | LMNA 3313/4885EPHX1 2873/4885KMT2A 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.